Apolipoprotein E*4 (APOE*4) Genotype Is Associated with Altered Levels of Glutamate Signaling Proteins and Synaptic Coexpression Networks in the Prefrontal Cortex in Mild to Moderate Alzheimer Disease

Supplemental Data

  • Supplemental Methods and Results (.pdf, 126 KB) - Supplemental Methods and Results, Including Supplemental Tables 2, 4, and 6
  • Fig S1 (.jpg, 26 KB) - Supplemental Figure 1. Distribution of last observed MMSE score by Braak Stage in AD subjects (N=59).
  • Fig S2 (.pdf, 258 KB) - Supplemental Figure 2. Unsupervised hierarchical clustering of assayed peptides in AD and control subjects identifies two subgroups.
  • Fig S3 (.pdf, 288 KB) - Supplemental Figure 3. Unsupervised hierarchical clustering of assayed peptides in AD and control subjects identifies two subgroups.
  • Fig S4 (.jpg, 41 KB) - Supplemental Figure 4. Classification of AD subjects into AD1 and AD2 groups derived from decision tree analysis of APOE*4, age, sex, and illness duration.
  • Fig S5 (.jpg, 182 KB) - Supplemental Figure 5. Comparison of protein alterations in AD1 and APOE4 targeted replacement mice. All proteins measured in AD1 and mice are shown as circles. Shaded circles are glutamate signaling proteins that were down-regulated in AD1 group. Diagonal line is a unity line.
  • Table S1 (.xlsx, 20 KB) - Supplemental Table 1. Protein expression in DLPFC of AD versus control subjects.
  • Table S3 (.xlsx, 21 KB) - Supplemental Table 3. Protein expression in DLPFC of FTLD versus control subjects.
  • Table S5 (.xlsx, 25 KB) - Supplemental Table 5. Comparison of protein expression in DLPFC and ERC of AD versus control subjects.
  • Table S7 (.xlsx, 20 KB) - Supplemental Table 7. Comparison of protein expression in cortex of APOE3 and APOE4 targeted replacement mice.
  • Table S8 (.xlsx, 25 KB) - Supplemental Table 8. Peptide coefficients of variation (CV) for DLPFC and ERC.